Putative virulence factors of Candida species colonizing respiratory tracts of patients

Microbial Ecology in Health and Disease

Volumn 16, Issue 4, 2004, Pages 214-217

  Shehabi, Asem A ^a   Nazzal, Shatha A ^a   Dajani, Naheel ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Candida species; Human respiratory tract; Jordan; Virulence factors

Indexed keywords

ASPARTIC PROTEINASE; HEMOLYSIN; PHOSPHOLIPASE; VIRULENCE FACTOR;

ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA TROPICALIS; FUNGAL COLONIZATION; FUNGAL VIRULENCE; FUNGUS CULTURE; HOSPITAL PATIENT; JORDAN; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYSTEM; STATISTICAL ANALYSIS; UNIVERSITY HOSPITAL;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; FUNGI; ISSATCHENKIA ORIENTALIS; JORDANIA;

EID: 11244301214     PISSN: 0891060X     EISSN: None     Source Type: Journal    
DOI: 10.1080/08910600410025419     Document Type: Article

References (29)

1. Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002; 40: 1298-302.
2. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungemia: pathogenicity and antifurigal resistance. J Hosp Infect 2002; 50: 243-60.
3. Singh N. Changing spectrum of invasive candidasis and its therapeutic implications. Clin Microbiol Infect 2001; 7: 1-7.
4. Abbas J, Bodey GP, Hanna HA, Mardani M, Girgaway E, Abi-Said D, et al. Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med 2000; 160: 2659-64.
5. Bukharie H A. Nosocomial candidemia in a tertiary care hospital in Saudi Arabia. Mycopathologia 2002; 153: 195-8.
6. Pelz RK, Lipsctt PA, Swoboda SM, Diener-West M, Powe NR, Brower RJ, et al. Candida infections: outcome and attributable ICU costs in critically ill patients. J Intensive Care Med 2000; 15: 255-61.
7. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996; 22: S89-94.
8. Hedderwick SA, Lyons MJ, Liu M, Vasquez JA, Kauffman CA. Epidemiology of yeast colonization in the intensive care unit. Eur J Clin Microbiol Infect Dis 2000; 19: 663-70.
9. Luzzati R, Amalfitano G, Lazzarini L, Soldani F, Bellino S, Solbiati M, et al. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary cart hospital. Eur J Clin Microbiol Infect Dis 2000; 19: 602-7.
10. Hazen KC. New emerging yeast pathogens. Clin Microbiol Rev 1995; 8: 462-78.
11. Verduyn-Lunel FM. Mies JF, Voss A. Nosocomial fungal infections: candidemia. Diagn Microbiol Infect Dis 1999; 34: 213-20.
12. Moosa MY, Sobel JD. Non-albicans Candida infections in patients with hematologic malignancies. Semin Respir Infect 2002; 17: 91-8.
13. Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 2002; 50: 56-65.
14. Odds FC, Gow NA, Brown AJB. Fungal virulence studies come of age. Genome Biology Reviews 2001; 2: 1009.1-4.
15. Calderone R, Fonzi W. Virulence factors of Candida albicans. Trends Microbiol 2001; 9: 327-35.
16. Fekete-Forgács K, Gyure L, Lenkey B. Changes of virulence factors accompanying the phenomenon of induced fluconazole resistance in Candida albicans. Mycoses 2000; 43: 273-9.
17. Fidel PL, Vasquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999; 12: 80-96.
18. Odd FC, Bernaerts R. CHROMagar Candida, a new differential medium for presumptive identification of clinically important Candida species. J Clin Microbiol 1994; 32: 1912-29.
19. Wu T, Samaranayake LP, Cao BY. In-vitro proteinase production by oral Candida albicans isolates from individuals with and without HIV infection and its attenuation by antimycotic agents. J Med Microbiol 1996; 44: 311-6.
20. Samaranayake LP, Raeside JM, MacFarlane TW. Factors affecting the phospholipase activity of Candida species in vitro. Sabouraudia 1984; 22: 201-7.
21. Luo G, Samaranayake LP, Yau JYY. Candida species exhibit differential in vitro hemolytic activities. J Clin Microbiol 2001; 39: 2971-4.
22. Shehabi AA, Dajani NF. Distribution of yeast species in clinical specimens: comparison of CHROMagar Candida medium with biochemical identification method. Dirasat/Medical and Biological Sciences 1998; 25: 125-9.
23. Pfaller MA. Diekema DJ. Role of sentinel surveillance of candidemia. Trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002; 40: 3551-7.
24. Martinez M, Lopez-Ribot L, Kirkpatrick WR, Coco BJ, Bachmann SP, Patterson TF. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol 2002; 40: 3135-9.
25. De Bernardis F, Sullivan PA, Cassone A. Aspartyl proteinases of Candida albicans and their role in pathogenicity. Med Mycol 2001; 39: 303-13.
26. Niewerth M, Korting HC. Phospholipases of Candida albicans. Mycoses 2001; 44: 361-7.
27. Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis. Rev Clin Microbiol Rev 2000; 13: 122-43.
28. Manns JM, Mosser DM, Buckley HR. Production of hemolytic factor by Candida albicans. Infect Immun 1994; 62: 5154-6.
29. Dar-Odeh NS, Shehabi AA. Oral candidiosis in patients with removable dentures. Mycoses 2003; 46: 187-91.